Volume 24, Number 11—November 2018
Research Letter
Estimating Latent Tuberculosis Infection Using Interferon-γ Release Assay, Japan
Tomoyasu Nishimura
, Masaki Ota, Masaaki Mori, Naoki Hasegawa, Hiroshi Kawabe, and Seiya Kato
, Masaki Ota, Masaaki Mori, Naoki Hasegawa, Hiroshi Kawabe, and Seiya Kato
Table
Characteristics and IGRA results of participants in a study of latent TB infection, Japan, 2016–2017*
| Characteristic | IGRA positive, no. (%, 95% CI), n = 8 | IGRA negative, no., n = 169 | p value† |
|---|---|---|---|
| Sex | |||
| F | 5 (5.1, 1.7–11.5) | 93 | 0.733 |
| M |
3 (3.8, 0.79–10.7) |
76 |
|
| Age, y | |||
| 20–29 | 6 (3.9, 1.4–8.3) | 148 | 0.278 |
| >30 |
2 (8.7, 1.1–28.0) |
21 |
|
| TB incidence rate in country of origin | |||
| <100 cases/100,000 population | 3 (2.4, 0.49–6.7) | 124 | 0.042‡ |
| >100 cases/100,000 population |
5 (10.0, 3.3–21.8) |
45 |
|
| Time living in Japan, y | |||
| <1 | 5 (3.4, 1.1–7.9) | 140 | 0.158 |
| >1 | 3 (9.4, 2.0–25.0) | 29 |
*IGRA, interferon-γ release assay; TB, tuberculosis.
†Differences between positive and negative groups were tested using Fisher exact test.
‡p<0.05.
Page created: October 16, 2018
Page updated: October 16, 2018
Page reviewed: October 16, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.